Motexafin lutetium

Drug Profile

Motexafin lutetium

Alternative Names: Antrin®; FP FP1; Lu-Tex; Lu-Tex/OPTRIN; Lutetium texaphyrin; Lutrin®; Optrin™; PCI 0123

Latest Information Update: 09 Jul 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Oxidants; Texaphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Atherosclerosis; Breast cancer; Cervical intraepithelial neoplasia; Coronary artery restenosis; Peripheral arterial disorders; Prostate cancer; Vascular restenosis

Most Recent Events

  • 28 Mar 2006 Motexafin lutetium is available for licensing worldwide (http://www.pharmacyclics.com)
  • 15 Nov 2004 Data presented at the American Heart Association Scientific Sessions (AHA-2004) have been added to the Ischaemic Heart Disease pharmacodynamics section
  • 12 Oct 2004 Data presented at the 16th Annual Transcatheter Cardiovascular Therapeutics conference (TCT-2004) have been added to the Ischaemic Heart Disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top